BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 27986523)

  • 1. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
    Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
    Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia.
    Tzoran I; Papadakis E; Brenner B; Valle R; López-Jiménez L; García-Bragado F; Riera-Mestre A; Villalobos A; Quintavalla R; Monreal M;
    Thromb Res; 2017 Mar; 151 Suppl 1():S11-S15. PubMed ID: 28262227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?
    Méan M; Limacher A; Stalder O; Angelillo-Scherrer A; Alberio L; Fontana P; Beer HJ; Rodondi N; Lämmle B; Aujesky D
    Am J Med; 2017 Oct; 130(10):1220.e17-1220.e22. PubMed ID: 28606797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.
    Caiano L; Kovacs MJ; Lazo-Langner A; Anderson DR; Kahn SR; Shah V; Kaatz S; Zide RS; Schulman S; Chagnon I; Mallick R; Rodger MA; Wells PS
    J Thromb Haemost; 2023 Mar; 21(3):553-558. PubMed ID: 36710196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM; Middeldorp S; Veeger NJ; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Circulation; 2010 Apr; 121(15):1706-12. PubMed ID: 20368522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both.
    Martinelli I; Bucciarelli P; Margaglione M; De Stefano V; Castaman G; Mannucci PM
    Br J Haematol; 2000 Dec; 111(4):1223-9. PubMed ID: 11167765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type.
    Sode BF; Allin KH; Dahl M; Gyntelberg F; Nordestgaard BG
    CMAJ; 2013 Mar; 185(5):E229-37. PubMed ID: 23382263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
    Eckman MH; Singh SK; Erban JK; Kao G
    Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.
    Donovan AK; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):724-8. PubMed ID: 24112753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
    Marchiori A; Mosena L; Prins MH; Prandoni P
    Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.
    Gerhardt A; Scharf RE; Beckmann MW; Struve S; Bender HG; Pillny M; Sandmann W; Zotz RB
    N Engl J Med; 2000 Feb; 342(6):374-80. PubMed ID: 10666427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type and location of venous thromboembolism in carriers of Factor V Leiden or prothrombin G20210A mutation versus patients with no mutation.
    Kovac M; Mitic G; Mikovic Z; Antonijevic N; Djordjevic V; Mikovic D; Mandic V; Rakicevic L; Radojkovic D
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):66-70. PubMed ID: 18796457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
    Cordoba I; Pegenaute C; González-López TJ; Chillon C; Sarasquete ME; Martin-Herrero F; Guerrero C; Cabrero M; Garcia Sanchez MH; Pabon P; Lozano FS; Gonzalez M; Alberca I; González-Porras JR
    Eur J Haematol; 2012 Sep; 89(3):250-5. PubMed ID: 22642978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.
    Marchetti M; Quaglini S; Barosi G
    QJM; 2001 Jul; 94(7):365-72. PubMed ID: 11435632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations.
    Couto E; Nomura ML; Barini R; Pinto e Silva JL
    Sao Paulo Med J; 2005 Nov; 123(6):286-8. PubMed ID: 16444389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
    Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
    Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
    Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.